EX-10.13 11 a18-19043_1ex10d13.htm EX-10.13 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Pennsylvania
Contract Type FiledMay 5th, 2020 JurisdictionTHIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of July 24, 2018 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Steven Gelone (the “Executive”) (together, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2019 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMarch 12th, 2019 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of March 21, 2018 among Nabriva Therapeutics US, Inc. (the “Company”), Nabriva Therapeutics plc and Jennifer Schranz (the “Executive”) (together, the “Parties”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
Contract Type FiledNovember 6th, 2018 Company Industry JurisdictionTHIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of July 24, 2018 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Steven Gelone (the “Executive”) (together, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2017 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of June 14, 2017 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Robert Crotty (the “Executive”) (together, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2017 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of July 10, 2017 among Nabriva Therapeutics US, Inc. (the “Company”), Nabriva Therapeutics plc and Francesco Maria Lavino (the “Executive”) (together, the “Parties”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2016 • Nabriva Therapeutics AG • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 9th, 2016 Company Industry JurisdictionTHIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of May 26, 2016 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Peter Wolf (the “Executive”) (together, the “Parties”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2016 • Nabriva Therapeutics AG • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 9th, 2016 Company Industry JurisdictionTHIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of May 26, 2016 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Steven Gelone (the “Executive”) (together, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2016 • Nabriva Therapeutics AG • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 9th, 2016 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of May 2nd 2016 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Gary L. Sender (the “Executive”) (together, the “Parties”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2016 • Nabriva Therapeutics AG • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 9th, 2016 Company Industry JurisdictionTHIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of May 26, 2016 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Elyse Seltzer, M.D. (the “Executive”) (together, the “Parties”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2016 • Nabriva Therapeutics AG • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 9th, 2016 Company Industry JurisdictionTHIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of June 17, 2016 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Colin Broom (the “Executive”) (together, the “Parties”).